Supplementary material

Bień B. Prevalent medication-related harm identified in patients admitted to a geriatric ward: cross-sectional and survival based contributors. Pol Arch Intern Med. 2021; 131: 9-16. doi:10.20452/pamw.15713

Supplementary Table S1 Medication Before Admission to and at Discharge from a Geriatric Ward in 301 Patients

	Pharmaceuticals or pharmaceutical group	Before admission n (%)	At discharge n (%)	P value (two-tailed test of difference in proportions)[a]
1	β-blocker(s)	191 (63.5)	205 (68.1)	0.55
2	Ca-blocker(s)	81 (26.9)	52 (17.3)	0.20
3	ACE-Inhibitor(s)	131 (43.5)	125 (41.5)	0.75
4	ARB (sartans)	62 (20.6)	41 (13.6)	0.36
5	α-blockers	39 (13.0)	39 (13.0)	1.00
6	Clonidine	4 (1.3)	0	
7	Methyldopa	2 (0.7)	1 (0.3)	0.96
8	Thiazides, including indapamide	60 (19.9)	44 (14.6)	0.48
9	Loop diuretics	78 (25.9)	95 (31.6)	0.41

10	Spironolactone or eplerenone	57 (18.9)	60 (19.9)	0.89
11	Digoxin	14 (4.6)	14 (4.6)	1.00
12	Propafenone	0	0	
13	Amiodarone	10 (3.3)	2 (0.7)	0.46
14	Trimetazidine	11 (3.7)	1 (0.3)	0.34
15	Nitrates	5 (1.7)	1 (0.3)	0.61
16	Statins	91 (30.2)	44 (14.6)	0.05
17	Fibrates	2 (0.7)	2 (0.7)	1.00
18	Allopurinol	22 (7.3)	13 (4.3)	0.08
19	Aspirin	88 (29.2)	72 (23.9)	0.45
20	Clopidogrel	7 (2.3)	6 (2.0)	0.89
21	Acenocoumarol/warfarin	29 (9.6)	25 (8.3)	0.11
22	New anticoagulants	40 (13.3)	53 (17.6)	0.57
23	Low Molecular Weight Heparin	6 (2.0)	16 (5.3)	0.16
24	Metformin	57 (18.9)	61 (20.3)	0.84
25	Sulfonylureas	35 (11.6)	17 (5.6)	<0.001
26	Insulin	33 (11.0)	32 (10.6)	0.96
27	Thyroid hormones	19 (6.3)	20 (6.4)	0.96
28	Thyreostatics	6 (2.0)	8 (2.7)	0.76
29	Paracetamol	53 (17.6)	82 (27.2)	0.20
30	Tramadol	37 (12.3)	46 (15.3)	0.69
31	NSAID	32 (10.6)	1 (0.3)	0.16

32	Opioids	5 (1.7)	9 (3.0)	0.59
33	Brain nootropic or vasodilator drugs[b]	110 (36.5)	2 (0.7)	0.39
34	Donepezil	27 (9.0)	48 (15.9)	<0.001
35	Rivastigmine	9 (3.0)	24 (8.0)	0.01
36	Memantine	23 (7.6)	39 (13.0)	<0.001
37	Levodopa	28 (9.3)	39 (13.0)	<0.001
38	Anti-epileptics	3 (1.0)	2 (0.7)	0.90
39	Dopamine receptor agonists	8 (2.7)	8 (2.7)	1.00
40	Monoamine oxidase inhibitors	3 (1.0)	1 (0.3)	0.77
41	Quetiapine	37 (12.3)	75 (24.9)	0.12
42	Risperidone	1 (0.3)	0	
43	Neuroleptics of the 1st generation (e.g., haloperidol, pernazine, promazine, sulpride, tiaprid)	16 (5.3)	1 (0.3)	<0.001
44	Tricyclic antidepressants	4 (1.3)	0	
45	Benzodiazepines	38 (12.6)	11 (3.6)	0.07
46	Hydroxyzine	27 (9.0)	0	
47	Mianserin	30 (10.0)	30 (10.0)	1.00
48	Serotonin/norepinephrine reuptake inhibitors	97 (32.2)	200 (66.4)	<0.001
49	Trazodone	11 (3.6)	14 (4.6)	0.61

50	Valproates	9 (3.0)	5 (1.7)	0.59
51	Carbamazepine	5 (1.7)	5 (1.7)	1.00
52	Pregabalin	3 (1.0)	43 (14.3)	0.51
53	Proton Pump Inhibitor	82 (27.2)	13 (4.3)	0.07
54	H2-antagonist	5 (1.7)	1 (0.3)	0.29
55	Purgative	5 (1.7)	20 (6.6)	0.04
56	Choleretics	32 (10.6)	26 (8.6)	0.79
57	Pancreatic	5 (1.7)	0	
58	Mebeverine	14 (4.7)	6 (2.0)	0.77
59	Protifar (proteins)	3 (1.0)	16 (5.3)	0.74
60	Corticosteroids	8 (2.7)	11 (3.7)	0.90
61	Inhaled drugs anti-COPD	19 (6.3)	18 (6.0)	0.96
62	Theophylline	11 (3.6)	1 (0.3)	0.48
63	Mesalazine	14 (4.7)	6 (2.0)	0.77
64	Antihistamines	4 (1.3)	0	
65	Diosmin/hesperidin	15 (5.0)	2 (0.7)	0.78
66	Vitamin D3	89 (29.6)	235 (78.1)	<0.001
67	Other than D3 vitamins	36 (12.0)	20 (6.6)	0.52
68	Minerals	57 (18.9)	23 (7.6)	0.21
69	Finasteride	14 (4.7)	11 (3.7)	0.90
70	Bisfosfonians	9 (3.0)	14 (4.7)	0.83
71	Other than above	64 (21.3)	17 (5.6)	0.13

Abbreviations: ARB, angiotensin receptor blockers; COPD, chronic obstructive pulmonary disease; NSAID, non-steroid anti-inflammatory drugs;

[a] a two-tailed test of difference in proportions was applied to compare the structure of relevant drug users between admission to geriatric ward and at discharge. The null hypothesis states that geriatric intervention led to no change in proportions of drug users.

[b] the following molecules were defined: betahistidine, vinpocetine, nicergoline, ginko biloba, piracetam, and similar.